Can AI help more people in Scotland survive skin cancer? How Scottish Health Boards can Unlock the Benefits of Teledermatology

Dermatology teams work tirelessly to serve their communities, but with urgent suspected skin cancer referrals rising every year,  Health Boards are facing a growing gap between demand and capacity – one that risks undermining their best efforts to ensure every patient receives timely access to care. 

In 2024, a dermatology workforce census reported just 61 consultant dermatologists working in Scotland’s Health Boards. To meet rising demand, Health Boards have sought to adopt new digital approaches to providing dermatology services that aim to improve patient access, ensure equity, and make better use of clinical time.

As NHS Scotland explores the future of digital dermatology, this one hour webinar will examine the role AI could play in supporting the goal of faster diagnosis and assessment of skin conditions for patients in Scotland.

Join Dr Keith Grimes, Founder of Curistica, as he chairs an expert panel for a discussion on how deploying ‘AI as a medical device’ autonomously within teledermatology pathways could release essential dermatologist capacity – and enable Scotland’s Health Boards to maintain and improve the volume of patients starting treatment within the national 62-day target.

Joining Keith on the panel will be:

  • Mr Ryan Kerstein, Consultant Plastic Surgeon, and Associate Medical Director for Research & Innovation at Buckinghamshire Healthcare NHS Trust

  • Rachael Dovey, Commercial Director, Skin Analytics

In a compelling, evidence-led discussion, we’ll cover:

  • The current challenges for dermatology: workforce gaps and the growing waiting lists for both urgent and routine dermatology
  • Current and future models for dermatology: What has been tried so far, and what alternatives exist?
  • Using regulated AI to unlock value:  How is DERM, the only AIaMD approved to make clinical decisions autonomously in the cancer space, being safely deployed in world-leading skin cancer pathways that are more efficient and cost-effective than traditional models.
  • Evaluating the benefits of AI: Using data published by NICE to assess the potential savings generated by AI – and the cost of proceeding down the current path.

Email: enquiries@skinanalytics.co.uk
LinkedIn: https://www.linkedin.com/company/skin-analytics/
X: https://x.com/skinanalytics

This event is free to attend for those working in the public and third sectors.

Event Details
Event Details
Sponsors